Guardant Health Announces Launch of the LUNAR Assay for Detection of Early-Stage Cancer and Recurrence to Academic and Biopharmaceutical Researchers
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- The LUNAR assay, a new blood-based assay intended to detect early-stage cancer and recurrence of disease, is now available from Guardant Health, Inc. (Nasdaq:GH), for research use by biopharmaceutical and academic researchers. The assay, was developed under the company’s LUNAR program for early-stage detection and recurrence monitoring. It is based on biological insights from more than 80,000 cancer patients tested with Guardant360, the industry leading comprehensive liquid biopsy test, as well as learnings from whole-genome sequencing liquid biopsy data. “Earlier intervention using precision medicine in oncology could potentially improve outcomes for substantial numbers of cancer patients. We believe this cutting-edge assay may be the catalyst to meaningfully increase survivorship, cures, and ultimately public health,” said Leena Das-Young, Pharm.D., General Manager of Guardant’s early-stage cancer program and Chief LUNA
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- FDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23 [Yahoo! Finance]Yahoo! Finance
- FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23Business Wire
- Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire
- Guardant Health, Inc. (NASDAQ: GH) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Guardant Health, Inc. (NASDAQ: GH) had its "neutral" rating re-affirmed by analysts at Guggenheim.MarketBeat
GH
Earnings
- 2/22/24 - Beat
GH
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- GH's page on the SEC website